Clinically, the serum Gal-3 levels in patients with HF are significantly increased [22,23,24], and the continuously increasing Gal-3 levels are often associated with a greater risk of adverse cardiovascular events [25,26]. This evidence concerns the gene LGALS3 and hydrops fetalis.